Literature DB >> 20421448

Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women.

Ola Landgren1, S Vincent Rajkumar, Ruth M Pfeiffer, Robert A Kyle, Jerry A Katzmann, Angela Dispenzieri, Qiuyin Cai, Lynn R Goldin, Neil E Caporaso, Joseph F Fraumeni, William J Blot, Lisa B Signorello.   

Abstract

Obesity and black race have been associated with excess risk of multiple myeloma. The association of obesity with monoclonal gammopathy of undetermined significance (MGUS) is unknown. Further, it is not known whether the increased risk of multiple myeloma and MGUS in blacks is related to socioeconomic status, genetic susceptibility, or both. We screened 1000 black and 996 white women (range, 40-79 years) of similar socioeconomic status for MGUS; the aim of the study was to assess MGUS risk in relation to obesity and race. A total of 39 (3.9%) blacks and 21 (2.1%) whites had MGUS. On multivariate analysis, obesity (odds ratio [OR] = 1.8; P = .04), black race (OR = 1.8; P = .04), and increasing age (> 55 vs < 43 years; OR = 2.5; P = .03) were independently associated with an excess risk of MGUS. Our findings support the hypothesis that obesity is etiologically linked to myelomagenesis. The 2-fold excess of MGUS among blacks compared with whites of similar socioeconomic status supports a role for susceptibility genes in MGUS.

Entities:  

Mesh:

Year:  2010        PMID: 20421448      PMCID: PMC2938127          DOI: 10.1182/blood-2010-01-262394

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States.

Authors:  Ola Landgren; Gloria Gridley; Ingemar Turesson; Neil E Caporaso; Lynn R Goldin; Dalsu Baris; Thomas R Fears; Robert N Hoover; Martha S Linet
Journal:  Blood       Date:  2005-10-06       Impact factor: 22.113

2.  Anthropometric characteristics and risk of multiple myeloma.

Authors:  Cindy K Blair; James R Cerhan; Aaron R Folsom; Julie A Ross
Journal:  Epidemiology       Date:  2005-09       Impact factor: 4.822

3.  Prevalence of monoclonal gammopathy of undetermined significance.

Authors:  Harvey Jay Cohen
Journal:  N Engl J Med       Date:  2006-06-29       Impact factor: 91.245

4.  Monoclonal gammopathy of undetermined significance: genetic vs environmental etiologies.

Authors:  Nikhil C Munshi
Journal:  Mayo Clin Proc       Date:  2007-12       Impact factor: 7.616

5.  Southern community cohort study: establishing a cohort to investigate health disparities.

Authors:  Lisa B Signorello; Margaret K Hargreaves; Mark D Steinwandel; Wei Zheng; Qiuyin Cai; David G Schlundt; Maciej S Buchowski; Carolyne W Arnold; Joseph K McLaughlin; William J Blot
Journal:  J Natl Med Assoc       Date:  2005-07       Impact factor: 1.798

6.  Prevalence of monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Dirk R Larson; Matthew F Plevak; Janice R Offord; Angela Dispenzieri; Jerry A Katzmann; L Joseph Melton
Journal:  N Engl J Med       Date:  2006-03-30       Impact factor: 91.245

7.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

Review 8.  Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies.

Authors:  Andrew G Renehan; Margaret Tyson; Matthias Egger; Richard F Heller; Marcel Zwahlen
Journal:  Lancet       Date:  2008-02-16       Impact factor: 79.321

9.  Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana.

Authors:  Ola Landgren; Jerry A Katzmann; Ann W Hsing; Ruth M Pfeiffer; Robert A Kyle; Edward D Yeboah; Richard B Biritwum; Yao Tettey; Andrew A Adjei; Dirk R Larson; Angela Dispenzieri; L Joseph Melton; Lynn R Goldin; Mary L McMaster; Neil E Caporaso; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2007-12       Impact factor: 7.616

10.  Anthropometric characteristics and non-Hodgkin's lymphoma and multiple myeloma risk in the European Prospective Investigation into Cancer and Nutrition (EPIC).

Authors:  Julie A Britton; Aneire E Khan; Sabine Rohrmann; Nikolaus Becker; Jakob Linseisen; Alexandra Nieters; Rudolf Kaaks; Anne Tjønneland; Jytte Halkjaer; Marianne Tang Severinsen; Kim Overvad; Tobias Pischon; Heiner Boeing; Antonia Trichopoulou; Victoria Kalapothaki; Dimitrios Trichopoulos; Amalia Mattiello; Giovanna Tagliabue; Carlotta Sacerdote; Petra H M Peeters; H Bas Bueno-de-Mesquita; Eva Ardanaz; Carmen Navarro; Paula Jakszyn; Jone M Altzibar; Göran Hallmans; Beatrice Malmer; Göran Berglund; Jonas Manjer; Naomi Allen; Timothy Key; Sheila Bingham; Hervé Besson; Pietro Ferrari; Mazda Jenab; Paolo Boffetta; Paolo Vineis; Elio Riboli
Journal:  Haematologica       Date:  2008-10-02       Impact factor: 9.941

View more
  59 in total

Review 1.  Second malignancies after multiple myeloma: from 1960s to 2010s.

Authors:  Anish Thomas; Sham Mailankody; Neha Korde; Sigurdur Y Kristinsson; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2012-02-06       Impact factor: 22.113

Review 2.  Inherited genetic susceptibility to multiple myeloma.

Authors:  G J Morgan; D C Johnson; N Weinhold; H Goldschmidt; O Landgren; H T Lynch; K Hemminki; R S Houlston
Journal:  Leukemia       Date:  2013-11-19       Impact factor: 11.528

3.  Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes.

Authors:  Syed J Mehdi; Sarah K Johnson; Joshua Epstein; Maurizio Zangari; Pingping Qu; Antje Hoering; Frits van Rhee; Carolina Schinke; Sharmilan Thanendrarajan; Bart Barlogie; Faith E Davies; Gareth J Morgan; Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2018-11-08       Impact factor: 6.998

4.  Obesity and the Transformation of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: A Population-Based Cohort Study.

Authors:  Su-Hsin Chang; Suhong Luo; Theodore S Thomas; Katiuscia K O'Brian; Graham A Colditz; Nils P Carlsson; Kenneth R Carson
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

Review 5.  Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Oncology (Williston Park)       Date:  2011-06       Impact factor: 2.990

6.  Use of trabecular bone score for risk stratification of patients with monoclonal gammopathy of undetermined significance.

Authors:  Jad G Sfeir; Tito D Pena Guzman; Lucia Bedatsova; Stephen M Broski; Matthew T Drake
Journal:  Bone       Date:  2020-04-28       Impact factor: 4.398

Review 7.  Myeloma and Bone Disease.

Authors:  Cristina Panaroni; Andrew J Yee; Noopur S Raje
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

Review 8.  Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma.

Authors:  Alexander M Lesokhin; Susan Bal; Ashraf Z Badros
Journal:  Cancer Immunol Res       Date:  2019-08       Impact factor: 11.151

Review 9.  Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.

Authors:  Amit Agarwal; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2012-12-05       Impact factor: 12.531

10.  Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach.

Authors:  Angela Baker; Esteban Braggio; Susanna Jacobus; Sungwon Jung; Dirk Larson; Terry Therneau; Angela Dispenzieri; Scott A Van Wier; Gregory Ahmann; Joan Levy; Louise Perkins; Seungchan Kim; Kimberly Henderson; David Vesole; S Vincent Rajkumar; Diane F Jelinek; John Carpten; Rafael Fonseca
Journal:  Blood       Date:  2013-02-19       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.